Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
NCT00322270 · View on ClinicalTrials.gov ↗
Study Summary
To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central venous access device.
Conditions Studied
Interventions
- DRUG Alfimeprase
Study Locations (18)
Florida
- Bethesda Research Center — Boynton Beach
- Pasco Hernando Oncology Associates — Brooksville
- Mercy Hospital — Miami
- Pasco Hernando Oncology Associate — New Port Richey
Illinois
- Medical and Surgical Specialists — Galesburg
- Cancer Center at Blessing Hospital — Quincy
Michigan
- Kalamazoo Hematology and Oncology — Kalamazoo
- Sparrow Cancer Center — Lansing
Missouri
- Comprehensive Cancer Care Clinic — Jefferson City
- The Center for Cancer Care and Research — St Louis
Ohio
- Gabrail Cancer Center — Canton
- Hematology/Oncology Consultants, Inc. — Columbus
Arizona
- Desert Oasis Cancer Center — Casa Grande
California
- Cancer Research & Prevention Center — Soquel
New Jersey
- UMDNJ-Robert Wood Johnson Medical School — New Brunswick
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322270
The ClinicalTrials.gov registry entry for NCT00322270 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is ARCA Biopharma, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention — of which Alfimeprase is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00322270 reports 18 study locations spanning 11 distinct geographic areas — top geographies include Florida, Illinois, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00322270 about?
NCT00322270 is a clinical study titled "Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters". To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central venous access device.
What is the current status of trial NCT00322270?
This trial is currently completed. It is a Phase 3 study. The study started on 2006-01.
What conditions does trial NCT00322270 study?
This clinical trial studies the following conditions: Thrombosis, Venous Thrombosis, Catheter Occlusion. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00322270?
The interventions under investigation include: Alfimeprase (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00322270?
This trial is sponsored by ARCA Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00322270 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.